Ranola ER500 mg

Ranola ER is an anti-anginal medicine indicated for the treatment of chronic angina (long-term management of stable angina pectoris), not for relief of an acute angina attack.

• Established / FDA-approved use: Treatment of chronic stable angina in adults. Ranola ER may be used as monotherapy, but it is most commonly used as add-on (combination) therapy when angina remains inadequately controlled with other anti-anginal agents such as beta-blockers, calcium channel blockers (e.g., amlodipine), or nitrates.
• Adjunct/combination use: When used together with amlodipine, beta-blockers, or nitrates, Ranola ER further reduces the frequency of angina episodes and increases exercise tolerance.
• Not indicated for the treatment of an acute anginal episode; it does not provide immediate relief and should not be relied upon for that purpose.
• Off-label / investigational use: Ranola ER has been studied off-label for its potential antiarrhythmic effects (e.g., in atrial fibrillation) in clinical trials, but this is not an approved indication and is not established as standard therapy; such use should be guided solely by a specialist physician.

Each extended-release (ER) tablet contains Ranolazine as the active pharmaceutical ingredient, commonly available in strengths of 500 mg and 1000 mg, along with pharmaceutically approved excipients that allow controlled/extended drug release.

Ranola ER is a piperazine-derivative anti-anginal agent formulated as an oral extended-release tablet. Unlike traditional anti-anginals, Ranola ER exerts its therapeutic effect largely independent of heart rate and blood pressure, which makes it a useful add-on option in patients whose angina is not adequately controlled by first-line agents. It is intended for long-term, chronic management of angina symptoms rather than acute symptom relief.

Ranola ER belongs to the anti-anginal agents class, specifically a piperazine-derivative selective inhibitor of the late inward sodium current in cardiac muscle.

Mechanism of action: Ranolazine selectively inhibits the late inward sodium current (late I_Na) in cardiac myocytes. During myocardial ischemia, this late sodium current is abnormally increased, leading to intracellular sodium and, secondarily via the sodium-calcium exchanger, intracellular calcium overload. This calcium overload increases diastolic wall tension, impairs myocardial relaxation, and raises myocardial oxygen demand. By inhibiting late I_Na, Ranolazine reduces this calcium overload, improves diastolic myocardial relaxation and left ventricular compliance, and reduces the frequency of anginal episodes.

Pharmacodynamics: Ranolazine produces its anti-anginal effect without clinically significant reductions in heart rate or blood pressure, distinguishing it from beta-blockers, calcium channel blockers, and nitrates.

Pharmacokinetics: Absorption of Ranolazine from the extended-release tablet is variable; steady-state plasma concentrations are generally achieved within 3 days of twice-daily dosing. Ranolazine is extensively metabolized, primarily by the CYP3A4 enzyme (with a minor contribution from CYP2D6), and is eliminated mainly via the kidneys with a smaller fraction excreted in feces. The elimination half-life is approximately 7 hours.

Ranola ER extended-release tablets should be swallowed whole with water, not crushed, broken, or chewed, as this would disrupt the extended-release mechanism and could lead to a rapid release of the full dose. It may be taken with or without food, at approximately the same times each day (morning and evening) to maintain steady blood levels.

Ranola ER is primarily metabolized by CYP3A4, making it prone to clinically significant interactions with drugs that affect this enzyme:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir and other HIV protease inhibitors, nefazodone): markedly increase Ranola ER plasma concentrations, raising the risk of dose-related QT prolongation; concomitant use is contraindicated.
• Potent CYP3A4 inducers (e.g., rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, St. John's Wort): substantially reduce Ranola ER plasma levels and efficacy; concomitant use is contraindicated.
• Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, fluconazole, grapefruit juice/products): increase Ranola ER exposure; if co-administration is necessary, the dose of Ranola ER should be limited (typically to 500 mg twice daily) and the patient monitored.
• Digoxin: Ranola ER increases digoxin plasma levels (via P-glycoprotein inhibition); digoxin levels should be monitored and the digoxin dose adjusted as needed after starting or stopping Ranola ER.
• Simvastatin: Ranola ER increases simvastatin exposure; simvastatin dose should be limited to 20 mg daily when used together with Ranola ER.
• Other QT-prolonging drugs (e.g., certain antiarrhythmics, antipsychotics, macrolides): additive risk of QT interval prolongation when combined with Ranola ER; avoid combination where possible and monitor closely if unavoidable.
• Metformin: in patients with renal impairment, Ranola ER can increase metformin exposure; monitor for metformin-related adverse effects.

The most commonly reported side effects of Ranola ER include:

• Dizziness
• Headache
• Constipation
• Nausea

Less common but clinically important effects include asthenia (weakness), hypotension, dose-related QT interval prolongation, and, rarely, syncope. Patients experiencing fainting, palpitations, severe dizziness, or signs of an allergic reaction while taking Ranola ER should seek prompt medical attention.

Pregnancy: Data on the use of Ranola ER in pregnant women are limited, and animal reproduction studies have not shown a clear risk, but human data are insufficient to rule out risk. Ranola ER should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under close physician supervision.

Lactation: It is not known whether Ranola ER is excreted in human breast milk. Because many drugs are excreted in breast milk and the effects on a nursing infant are unknown, a decision should be made to discontinue nursing or discontinue Ranola ER, taking into account the importance of the drug to the mother, in consultation with a physician.

• QT interval prolongation: Ranola ER causes dose-related prolongation of the QT interval. Use with caution in patients with congenital long QT syndrome, a family history of long QT syndrome, known acquired QT prolongation, uncorrected hypokalemia or hypomagnesemia, or in combination with other QT-prolonging drugs.
• Not for acute angina: Ranola ER is intended for chronic management of angina; it has not been shown to provide relief during an acute anginal attack and should not be used for that purpose.
• Renal impairment: Use with caution; rare cases of acute kidney injury have been reported, particularly in patients with pre-existing renal impairment (see Dosage and Administration, Renal Impairment).
• Hepatic impairment: Contraindicated in hepatic cirrhosis (see Contraindications); use with caution in mild hepatic impairment.
• Elderly and low body weight patients: May experience a higher incidence of adverse effects such as dizziness, nausea, hypotension, and syncope; monitor closely (see Use in Special Populations).
• Drug interactions: Significant interactions exist with CYP3A4 inhibitors/inducers and other agents; review the Drug Interactions section before co-prescribing.

Reported symptoms of Ranola ER overdose include dizziness, nausea, vomiting, hypotension, double vision (diplopia), confusion, lethargy, tremor, paresthesia, and, rarely, syncope. There is no specific antidote for Ranola ER overdose. Because Ranola ER is highly protein-bound, hemodialysis is unlikely to be effective in removing the drug. In case of a suspected overdose, seek immediate medical attention or contact emergency services/a poison control center; treatment should be supportive, with monitoring of cardiac rhythm (ECG) given the risk of QT prolongation, and management of symptoms as clinically indicated in a medical facility.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Ranola ER have not been established in pediatric patients. Its use in children and adolescents is not recommended.

Elderly (Geriatric) Use

Elderly patients (particularly those over 75 years) may have a higher incidence of adverse reactions to Ranola ER, including dizziness, nausea, hypotension, and syncope, likely related to higher plasma concentrations. No specific dose reduction is mandated based on age alone, but close clinical monitoring is advised.

Renal Impairment

Ranola ER should be used with caution in mild-to-moderate renal impairment and has not been well studied in severe renal impairment; monitor renal function during treatment (see Precautions and Warnings).

Hepatic Impairment

Ranola ER is contraindicated in patients with hepatic cirrhosis; caution is advised even in milder hepatic impairment.

Low Body Weight

Patients with low body weight (≤60 kg) may have higher Ranola ER plasma concentrations and a somewhat higher rate of adverse reactions; monitor accordingly.

Ranola ER is used for long-term, chronic maintenance treatment of angina rather than a short, fixed course. Treatment is generally continued for as long as the prescribing physician determines it is providing symptomatic benefit and is well tolerated, with periodic clinical review (including assessment of QT interval, renal function, and concomitant medications) to confirm continued appropriateness of therapy.

Ranolazine is classified as: Anti-anginal agent; piperazine derivative; selective inhibitor of the late inward cardiac sodium current.

Ranolazine selectively inhibits the late inward sodium current (late I_Na) in cardiac myocytes, which is pathologically increased during myocardial ischemia. By reducing this abnormal sodium influx, Ranolazine lowers intracellular sodium-dependent calcium overload (via the sodium-calcium exchanger), decreases diastolic ventricular wall tension, improves myocardial relaxation and compliance, and reduces myocardial oxygen demand — thereby reducing the frequency of angina episodes without clinically significant effects on heart rate or blood pressure.

C

Ranola ER is not approved for use in pediatric patients. Safety and efficacy have not been established in individuals under 18 years of age, and its use in this population is not recommended outside of a controlled clinical trial setting.